The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Open accessAbstract
Taking the Myc: Despite nearly 30 years of research into the mechanisms by which Myc oncogene dysregulation contributes to tumorigenesis, there are still no effective therapies that inhibit Myc activity. Kessler et al. (p. 348 , published online 8 December; see the Perspective by Evan ) searched for gene products that support Myc-driven tumorigenesis. One pharmacologically tractable target that emerged from the screen was the SUMO-activating enzyme complex SAE1/2, which catalyzes a posttranslational modification (SUMOylation) that alters protein behavior and function. SUMOylation was found to control the Myc transcriptional response, and its inhibition caused mitotic defects and apoptosis in Myc-dependent breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Self-citationAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Hay, R. T. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.012 · Cited by 1,622
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Cited by
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Sumoylation: A Regulatory Protein Modification in Health and Disease
Flotho, A., & Melchior, F. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061909-093311 · Cited by 1,097
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Genome-wide Chromatin State Transitions Associated with Developmental and Environmental Cues
Zhu, J., Adli, M., Zou, J. Y., Verstappen, G., Coyne, M., Zhang, X., Durham, T., Miri, M., Deshpande, V., De Jager, P. L., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.033 · Cited by 545
A comprehensive compilation of SUMO proteomics
Hendriks, I. A., & Vertegaal, A. C. O. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.81 · Cited by 514
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Hsu, T. Y.-T., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015) · Nature · doi:10.1038/nature14985 · Cited by 492
Self-citationSUMO and the robustness of cancer
Seeler, J.-S., & Dejean, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.143 · Cited by 429
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Terunuma, A., Putluri, N., Mishra, P., Mathé, E. A., Dorsey, T. H., Yi, M., Wallace, T. A., Issaq, H. J., Zhou, M., Killian, J. K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71180 · Cited by 428
“In a proof-of-principle experiment, we examined 2HG levels in hTERT immortalized human mammary epithelial cells with inducible upregulation of MYC (27).”
Self-citationHoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Signalling mechanisms and cellular functions of SUMO
Vertegaal, A. C. O. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00500-y · Cited by 376
Chang, H.-M., & Yeh, E. T. H. (2020) · Physiological Reviews · doi:10.1152/physrev.00025.2019 · Cited by 355
Oxidants, antioxidants and the current incurability of metastatic cancers
Watson, J. (2013) · Open Biology · doi:10.1098/rsob.120144 · Cited by 354
ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression
Wen, H., Li, Y., Xi, Y., Jiang, S., Stratton, S., Peng, D., Tanaka, K., Ren, Y., Xia, Z., Wu, J., et al. (2014) · Nature · doi:10.1038/nature13045 · Cited by 343
The post-translational modification, SUMOylation, and cancer (Review)
Han, Z.-J., Feng, Y.-H., Gu, B.-H., Li, Y.-M., & Chen, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4280 · Cited by 334
Target gene-independent functions of MYC oncoproteins
Baluapuri, A., Wolf, E., & Eilers, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0215-2 · Cited by 310
Park, J. H., Vithayathil, S., Kumar, S., Sung, P.-L., Dobrolecki, L. E., Putluri, V., Bhat, V. B., Bhowmik, S. K., Gupta, V., Arora, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.004 · Cited by 313
Self-citationStrategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
Eifler, K., & Vertegaal, A. C. O. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.006 · Cited by 290
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
Zhao, D., Pan, C., Sun, J., Gilbert, C., Drews-Elger, K., Azzam, D. J., Picon-Ruiz, M., Kim, M., Ullmer, W., El-Ashry, D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.257 · Cited by 267
Self-citationLiang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-18-3374 · Cited by 75
Rousseaux, M. W. C., Vázquez-Vélez, G. E., Al-Ramahi, I., Jeong, H.-H., Bajić, A., Revelli, J.-P., Ye, H., Phan, E. T., Deger, J. M., Perez, A. M., et al. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0254-18.2018 · Cited by 61
Self-citationLi, Y.-J., Du, L., Wang, J., Vega, R., Lee, T. D., Miao, Y., Aldana-Masangkay, G., Samuels, E. R., Li, B., Ouyang, S. X., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.026 · Cited by 50
Targeting post-translational modification of transcription factors as cancer therapy
Qian, M., Yan, F., Yuan, T., Yang, B., He, Q., & Zhu, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.005 · Cited by 47
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
Improved Peptide Search for Identification of SUMO and Sequence-Based Modifiers, in MaxSBM
Lennartsson, C., Kyriakidou, P., Nielsen, M. L., Olsen, J. V., Cox, J., & Hendriks, I. A. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101589
Metadata
- Authors
- Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A. C., Solimini, N. L., Bernardi, R. J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C. K., Creighton, C. J., Hilsenbeck, S. G., Schiff, R., Shaw, C. A., Elledge, S. J., & Westbrook, T. F.
- Venue
- Science
- Published
- 2012-01-20
- Volume
- 335
- Issue
- 6066
- Pages
- 348-353
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1987344383
- Cited by
- 433
- References
- 39
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.